Abstract
In this chapter, we introduce a novel concept for an effective treatment of advanced prostate cancer, using our understanding of transforming growth factor (TGF)-β signaling. TGF-β plays an important role in prostate cancer development and progression. Two characteristic features of TGF-β signaling in aggressive prostate cancer are a reduced sensitivity to TGF-β and an overproduction of TGF-β. A reduced sensitivity to TGF-β removes the inhibitory effect of TGF-β and provides a growth advantage for the cancer cells. An overproduction of TGF-β endows cancer cells the ability to metastasize, to enhance angiogenesis, and to evade host’s immune surveillance program, leading to tumor progression and metastasis. TGF-β is a potent tumor-induced immunosuppression. A therapeutic strategy rending host immune cells insensitive to TGF-β should offer an effective approach to eradicate advanced prostate cancer.
Key Words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Blattman, J. N. and Greenberg, P. D. (2004). Cancer immunotherapy: A treatment for the masses. Science 305, 200–205.
Yannelli, J. R., Hyatt, C., McConnell, S., et al. (1996). Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65, 413–421.
Tjoa, B. A., Lodge, P. A., Salgaller, M. L., Boynton, A. L., and Murphy, G. P. (1999). Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J. Clin. 49, 117–128.
DeLarco, J. E. and Todaro, G. J. (1978). Growth factors from murine sarcoma virus-transformed cells. Proc. Nat. Acad. Sci. USA 75, 4001–4005.
Lee, C., Sintich, S. M., Mathews, E. P., and Shah, A. H. (1999). Transforming growth factor-β in benign and malignant prostate. Prostate 39, 285–290.
Jakowlew, S. B., Dillard, P. J., Kondaiah, P., Sporn, M. B., and Roberts, A. B. (1988). Complementary deoxyribonucleic acid cloning of a novel transforming growth factor-beta messenger ribonucleic acid from chick embryo chondrocytes. Mol. Endocrinol. 2, 747–755.
Kondaiah, P., Sands, M. J., Smith, J. M., et al. (1990). Identification of a novel transforming growth factor beta (TGF-beta5) mRNA in Xenopus laevis. J. Biol. Chem. 265, 1089–1093.
Derynck R., Jarret, J. A., Chen, E. Y., et al. (1985). Human transforming growth factor-beta complementary DNA sequences and expression in normal and transformed cells. Nature 316, 701–705.
Madison, L., Webb, N. R., Rose, T. M., et al. (1988). Transforming Growth Factor-beta2: cDNA cloning and sequence analysis. DNA 7, 1–8.
Sutkowski, D. M., Fong, C.-J., Sensibar, J. A., et al. (1992). Interaction of epidermal growth factor and transforming growth factor-β1 in human prostatic epithelial cell in culture. Prostate 21, 133–143.
Wilding, G. (1991). Response of prostate cancer cells to peptide growth factor: Transforming Growth Factor-beta. Cancer Surv. 11, 147–163.
Dijke, P. T., Goumans, M. J., Itoh, F., and Itoh, S. (2002). Regulation of Cell Proleferation by Smad Proteins. J. Cell Physiol. 191, 1–16.
Robert, A. B. and Sporn, M. B. (1990). In: Peptide Growth Factors and Their Receptors, Part I, Vol. 95 (Sporn, M. B., Roberts, A. B., eds.). Berlin: Springer-Verlag, pp. 419–472.
Gentry, L. E., Liobin, M. N., Purchio, A. F., and Marquardt, H. (1988). Type 1 Transforming Growth Factor-beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary. Mol. Cell Biol., 8, 4162–4168.
Massagué, J. (1998). TGF-beta signal transduction. Ann. Rev. Cell Biol. 67, 753–791.
Gentry, L. E., Webb, N. R., Lim, G. J., Brunner, A. M., and Ranchalis, J. E. (1987). Molecular events in the processing of recombinant typel pre-pro-transforming Growth Factor-beta to mature polypeptide. Mol. Cell Biol. 7, 3418–3427.
Miyazono, K., Ichijo, H., and Heldin, C. H. (1993). Growth Factor-beta: latent forms, binding proteins and receptor. Transforming Growth Factor 8, 11–22.
Cheifetz, S., Hernandez, H., Laiho, M., Ten Dijke, P., Iwata, K. K., and Massagué, J. (1990). Distinct Transforming Growth Factor-beta receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 165, 20,533–20,538.
Cheifetz, S., Ling, N., Guilemin, R., and Massague, J. (1988). A surface component on GH3 pituitary cells that recognizes Transforming Growth Factor-beta, actin and inhibitin. J. Biol. Chem. 263, 17,225–17,228.
Lopez-Casillas, F., Chiefetz, S., Doody, J., Andres, J. L., Lane, W. S., and Massagué, J. (1991). Structure and expression the membrane proteoglycan betalycana component. Cell 67, 785–795.
Lopez-Casillas, F., Wrana, J. L., and Massagué, J. (1993). Betaglycan presents ligand to the TGF signaling receptor. Cell 73, 1435–1444.
Rodriguez, C., Chen, F., Weinberg, R. A., and Lodish, H. F. (1995). Cooperative binding of Transforming Growth Factor-beta2 to the TβR-I and II TGF-beta receptors. J. Biol. Chem. 270, 15,919–15,922.
Sankar, M., Mahooti-Brooks, N., Centrella, M., McCarthy, T. H., and Madri, J. A. (1995). Expression of Transforming Growth Factor TβR-III receptor in vascular endothelial cells increase their responsiveness to transforming growth Factor 2. J. Biol. Chem. 270, 2769–2775.
Kingsley, D. M. (1994). The TGF-β Superfamily: new members, new receptors, and new genetic tests of function in different organisms (review). Genes Dev. 8, 133–146.
Wrana, J. L., Attisan, L., Wieser, R., Ventura, F., and Massagué, J. (1994). Mechanism of activation of the TGF-beta receptor. Nature 370, 341–347.
Kim, W. S., Park, C., Jung, Y. S., et al. (1999). Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res. 19, 301–306.
Kim, I. Y., Ahn, H. J., Lang, S., et al. (1998). Loss of expression of transforming growth factor-β receotpors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res. 4, 1625–1630.
Massagué, J. (2000). How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 1, 169–178.
Massagué, J. (2000). TGF-beta signal in Growth Control, Cancer, and Heritalble Disorders. Cell 103, 295–309.
Huse, M., Chen, Y. G., Massagué, J., and Kuriyan, J. (1999). Crystal structure of the cytoplasmic domain of the type I TGF-β receptor in complex with FKBP. Cell 96, 425–436.
Lo, R. S. and Massagué, J. (1999). Ubiquitin-dependent degradation of TGF-β activated SMAD2. Nat. Cell Biol. 1, 472–478.
De Caestecker, M. P., Piek, E., and Roberts, A. B. J. (2000). The role of TGF-β signaling in cancer. Natl. Cancer Inst., 92, 1388–1402.
Eilers, M., Schirm, S., and Bishop, J. M. (1991). The MYC protein activates transcription of the $-prothymosin gene EMBO J. 10, 133–141.
Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. (1991). Competitive expression in an IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6, 1915–1922.
Evan, G. I., Wyllie, A. H., Gilbert, C. S., et al. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119–128.
Henriksson, M. and Lüscher, B. (1996). Proteins of the myc network: essential regulators of cell growth and differentiation. Cancer Res. 68, 109–182.
Lemaitre, J. M., Buckle, R. S., and Mechali, M. (1996). c-Myc in the control of cell proliferation and embryonic development. Adv. Cancer Res. 70, 96–144.
Sherr, C. J. and Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of GI-phase progression. Genes Dev. 13, 1501–1512.
Graham, A., Koentges, G., and Lumsden, A. (1996). Neural crest apoptosis and the establishment of cranofacial pattern: an honorable death. Mol. Cell Neurosci. 8, 76–83.
Nguyen, A. V. and Pollard, J. W. (2000). Tansforming growth factor β 3 induces cell death during the first stage of mammary gland involution. Devel. 127, 3107–3118.
Gold, L. L. (1999). The role for transforming growth factor β (TGF-β) in human cancer. Crit. Rev. Oncog. 10, 303–360.
Kim, I. Y., Ahn, H. J., Zelner, D. J., et al. (1996). Loss of expression of Transforming Growth Factor-beta receptors type I and type II correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 2, 1255–1261.
Prime, S. S., Davies, M., Pring, M., and Paterson, I. C. (2004). The role of TGF-beta in epithelial malignancy and its relevance to the pathogenesis of oral cancer (part II). Crit. Rev. Oral. Biol. Med. 15, 337–347.
Markowitz, S., Wang, J., Myehoff, L., et al. (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336–1338.
Kang, S. H., Bang, Y. J., Im, Y. H., et al. (1999). Transcriptional repression of transforming growth factor beta tpe I receptor gene by DNA methylation results in the development of TGF-β resistance in gastric cancer. Oncogene 18, 7280–7296.
Kim, S. J., Im, Y. H., Markowitz, S. D., and Bang, Y. J. (2000). Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev. 11, 159–168.
Osada, H., Tatematsu, Y., Masuda, A., et al. (2001). Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res. 61, 8331–8339.
Seijo, E. R., Song, H., Lynch, M. A., et al. (2001). Identification of genetic alterations in the TGF-beta type II receptor gene promoter. Mutat. Res. 483, 19–26.
Zhang, Q., Rubenstein, J. N., Jang, T. L., et al. (2005). Insensitivity to transforming growth factor-β signaling is resulted from promoter methylation of cognate receptors in human prostate cancer cells. Mol. Endo. 19, 2390–2399.
Chen, T. C., Hinton, D. R., Yong, V. W., and Hofman, F. M. (1997). TGF-beta2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. J. Neuroimmunol. 73, 155–161.
Xu, X. L., Brodie, S. G, Yang, X., et al. (2000). Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. J. Virol. 19, 1868–1874.
Abou-Shady, M., Bear, H. U., Friess, H., et al. (1999). Transforming growth factor betas and their signaling receptors in Human hepatocellular carcinoma. Am. J. Surg. 177, 209–215.
Steiner, M. S., Zhou, Z. Z., Tonb, D. C., and Barrack, E. R. (1994). Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135, 2240–2247.
Perry, K. T., Anthony, C. T., and Steiner, M. S. (1997). Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate 33, 133–140.
Wikstrom, P., Bergh, A., and Damber, J. E. (2000). Metastasis, Immunosuppression, transforming growth factor-beta 1 and Prostate Cancer (Review). Scand. J. Urol. Nephrol. 34, 85–94.
Zhang, Q., Yang, X., Pins, M., et al. (2005). Adoptive transfer of tumor reactive TGF-β insensitive CD8+ T cells: Eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761–1769.
Barrack, E.R. (1997). An experimental model simulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer. Prostate 31, 61–70.
Vieweg, J., Heston, W. D., Gilboa, E., and Fair, W. R. (1994). TGF-β on prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 24, 291–298.
Steiner, M. S. and Barrack, E. R. (1992). Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol. 6, 15–25.
Matthews, E., Yang, T., Janulis, L., et al. (2000). Down regulation of TGF-β1 production restores immunogenicity in prostate cancer cells. Brit. J. Cancer 83, 519–525.
de Visser, K. E. and Kast, M. W. (1999). Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukimia 13, 1188–1199.
Kao, J. Y., Gong, Y., Chen, C. M., Zheng, Q. D., and Chen, J. J. (2003). Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 170, 3806–3811.
Hsieh, C. L., Chen, D. S., and Hwang, L. H. (2000). Tumor-induced immunosuppression: a barrier to immunotherapy of large tumor by cytokine-secreting tumor vaccine. Hum. Gene Ther. 11, 681–692.
Scarpa, S., Coppa, A., and Ragano-Caracciolo, M. (1996). Transforming Growth Factor beta regulates differentiation and prolfieration of human neuroblastoma. Exp. Cell Res. 229,147–154.
Poppema, S., Potters, M., Visser, L., and Van Den Berg, A. M. (1998). Immune escape mechanisms in Hodhkin’s disease. Ann. Oncol. 9(Suppl. 5), S21–S24.
Levinson, W. and Jawetz, E. (1998). Medical Microbiology and Immunology, Chapter 58. pp. 360–361.
Wojtowicz-Praga, S. (1997). Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20, 165–177.
Letterio, J. J. and Roberts, A. B. (1998). Regulation of immune responses by TGF-β. Ann. Rev. Immunol. 13, 51–69.
Fortunel, N. O., Hatzfeld, A., and Hatzfeld, J. (2000). Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis. Blood 96, 2022–2036.
Gorelik, L. and Flavell, R. A. (2000). Transforming growth factor-1 null mutationin mice causes excessive inflammatory response and early death. Immunity. 12, 171–181.
Shah, A. H., Tabayoyong, W. B., Kimm S. Y., Kim, S. J., Parijs, L. V., and Lee, C. (2002). Selection of the T cell repertoire. J. Immunol. 169, 3485–3491.
Won, J., Hongtae, K., Eun, J. P., Hong, Y., Kim, S. J., and Yun, Y. (1999). Influence of TGF-b on murine thymoctyes development in fetal thymus organ culture. Cancer Res. 9, 1273–1277.
Fakhrai H., Dorigo O., Shawler D., et al. (1996). TGF-β down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. Proc. Natl. Acad. Sci. USA 93, 2909–2914.
Kulkarni, A. B., Huh, C. G., Becker, D., et al. (1993). The host-tumor immune conflict: from immunosuppression to resistance and destruction. Proc. Natl. Acad. Sci. USA 90,770–774.
Sebzda, E., Mariathasan, S., Ohteki, T., Jones, R., Bachmann, M. F., and Ohashi, P.S. (1999). A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Ann. Rev. Immunol. 17, 829–874.
Plum, J., De Smedt, M., Leclercq, G., and Vandekerckhove, B. (1995). Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. J. Immunol. 154, 5789–5798.
Tang, J., Nuccie, B. L., Ritterman, I., Liesveld, J. L., Abboud, C. N., and Ryan, D. H. (1997). Eradication of established intracranial rat gliomas by transforming growth factor b antisense gene therapy. J. Immunol. 159, 117–125.
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., and Blay, J. Y. (1997). Tumorigenicity of mouse thymona is suppressed by soluble type II transforming growth factor b receptor therapy. Immunol. Today 18, 493–497.
Torre-Amione, G., Beauchamp, R. D., Koeppen, H., et al. (1990). Peripheral selection of the T cell repertoire. Proc. Natl. Acad. Sci. USA. 87, 1486–1490.
Arteaga, C. L., Carty-Dugger, T., Moses, H., Hurd, S., and Pietenpol, J. (1993). Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-soecific triggering. Cell Growth Differ. 4, 1647–1651.
Rocha, B. and von Boehmer, H. (1991). Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Science 251, 1225–1228.
Miller, A., Lider, O., Roberts, A. B., Sporn, M. B., and Weiner, H. L. (1992). Transforming growth factor beta-1 (TGF-β1) controls statement of major histocompatibility genes in the post-natal mouse: Aberrant histocompatibility antigen statement in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl. Acad. Sci. USA, 89, 421–425.
Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M., and Palladino, M. A. (1992). SLE-like autoantibodies and Sjogren’s syndrome-like lymphoproliferation in TGF-β knockout mice. Proc. Natl. Acad. Sci. USA. 89, 7375–7379.
Geiser, A. G., Letterio, J. J., Kulkarni, A. B., Karlsson, S., Roberts, A. B., and Sporn, M. B. (1993). T-cell apoptosis detected in situ during positive and negative selection in the thymus. Proc. Natl. Acad. Sci. USA. 90, 9944–9948.
Dong, H., Geiser, A. G., Letterio, J. J., et al. (1995). Early progression of thymocytes along the CD4/CD8 development pathway is regulated by a subset of thymic epithelial cells statement transforming growth factor beta. J. Immunol. 155, 3205–3212.
Surh, C. D. and Sprent, J. (1994). Animal models of autoimmunity and their relevance to human diseases. Nature 372, 100–103.
Takahama, Y., Letterio, J. J., Suzuki, H., Farr, A. G., and Singer, A. (1994). Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. J. Exp. Med. 179, 1495–1506.
Sakaguchi, S. (2000). Curr. Opin. Immunol. 12, 684–690.
Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A., and Weiner, H. L. (1994). Reconsitituion of lethally irradiated mice with TGF-β insensitive bone marrow leads to myeloid expansion and inflammatory disease. Science 265, 1237–1231.
Shah, A. H., Tabayoyong, W. B., Kundu, S. D., et al. (2002). Suppression of tumor metastasis by blockade of TGF-β signaling in bone marrow cells through a retroviral mediated gene therapy in mice. Cancer Res. 62, 7135–7138.
Bollard, C. M., Rossig, C. M., Calonge, J., et al. (2002). Adapting A TGF-β-related tumor protection strategy to enhance anti-tumor immunity. Blood 99, 3179–3187.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Lee, C. et al. (2007). Role of Transforming Growth Factor-β in Immunotherapy of Prostate Cancer. In: Chung, L.W.K., Isaacs, W.B., Simons, J.W. (eds) Prostate Cancer. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59745-224-3_10
Download citation
DOI: https://doi.org/10.1007/978-1-59745-224-3_10
Publisher Name: Humana Press
Print ISBN: 978-1-58829-696-2
Online ISBN: 978-1-59745-224-3
eBook Packages: MedicineMedicine (R0)